Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

Sofie H.M. Manders*, Wietske Kievit, Eddy Adang, Herman L. Brus, Hein J. Bernelot Moens, Andre Hartkamp, Lidy Hendriks, Elisabeth Brouwer, Henk Visser, Harald E. Vonkeman, Jos Hendrikx, Tim L. Jansen, Rene Westhovens, Mart A.F.J. van de Laar, Piet L.C.M. van Riel

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

64 Citations (Scopus)
32 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions